BR9910763A - Rotaviruses non-structural protein 4 (nsp4) antigenic composition, processes to protect a mammalian host against disease caused by rotaviruses, and to improve diarrheal symptoms in a mammalian host, isolated and purified nucleic acid sequence, plasmid containing a nucleic acid sequence isolated and purified host cell and process to produce an alternative form of rotavirus nsp4 - Google Patents
Rotaviruses non-structural protein 4 (nsp4) antigenic composition, processes to protect a mammalian host against disease caused by rotaviruses, and to improve diarrheal symptoms in a mammalian host, isolated and purified nucleic acid sequence, plasmid containing a nucleic acid sequence isolated and purified host cell and process to produce an alternative form of rotavirus nsp4Info
- Publication number
- BR9910763A BR9910763A BR9910763-5A BR9910763A BR9910763A BR 9910763 A BR9910763 A BR 9910763A BR 9910763 A BR9910763 A BR 9910763A BR 9910763 A BR9910763 A BR 9910763A
- Authority
- BR
- Brazil
- Prior art keywords
- nsp4
- nucleic acid
- rotaviruses
- acid sequence
- isolated
- Prior art date
Links
- 101710159910 Movement protein Proteins 0.000 title abstract 10
- 101710144117 Non-structural protein 4 Proteins 0.000 title abstract 10
- 241000702670 Rotavirus Species 0.000 title abstract 5
- 150000007523 nucleic acids Chemical group 0.000 title abstract 3
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108700015434 rotavirus NS28 Proteins 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title 2
- 101800000514 Non-structural protein 4 Proteins 0.000 title 1
- 230000000741 diarrhetic effect Effects 0.000 title 1
- 239000013612 plasmid Substances 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 235000013922 glutamic acid Nutrition 0.000 abstract 2
- 239000004220 glutamic acid Substances 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
''PROTEìNA NãO-ESTRUTURAL 4 (NSP4) DE ROTAVìRUS COMPOSIçãO ANTIGêNICA, PROCESSOS PARA PROTEGER UM HOSPEDEIRO MAMìFERO CONTRA DOENçA CAUSADA POR ROTAVìRUS, E PARA MELHORAR SINTOMAS DIARRéICOS EM UM HOSPEDEIRO MAMìFERO, SEQUêNCIA DE áCIDO NUCLEICO ISOLADA E PURIFICADA, PLASMìDEO CONTENDO UMA SEQUêNCIA DE áCIDO NUCLEICO ISOLADA E PURIFICADA, CéLULA HOSPEDEIRA, E, PROCESSO PARA PRODUZIR UMA FORMA ALTERNATIVA DE NSP4 DE ROTAVìRUS''. A proteína não-estrutural 4 (NSP4) na cepa de rotavírus ATCC SA11 apresenta uma histidina na posição de aminoácido 47. Esta forma substituída é mais citotóxica do que a NSP4 da cepa rotavírus Austrália, que apresenta uma aspargina na posição de aminoácido 47. A histidina na posição de aminoácido 47 é mutagenizada a outro aminoácido para produzir uma forma alternativa de NSP4 que apresenta reduzida toxicidade, enquanto mantém sua antigenicidade e imunogenicidade. Pelo fato de a NSP4 apresentar um ácido glutâmico na posição de aminoácido 48 o mesmo é mais citotóxico do que a NSP4 apresentando uma lisina na posição de aminoácido 48. A lisina na posição de aminoácido 48 é mutagenizada a outro aminoácido diferente de ácido glutâmico para produzir uma forma alternativa de NSP4 que apresenta reduzida toxicidade, enquanto mantém sua antigenicidade e imunogenicidade.'' NON-STRUCTURAL PROTEIN 4 (NSP4) FROM ROTAVÍRUS ANTIGENIC COMPOSITION, PROCESSES TO PROTECT A MAMMALIAN GUEST AGAINST DISEASE CAUSED BY ROTAVIRUS, AND TO IMPROVE HUMOROUS, HUMOROUS, HUMOROUS WOMEN IN A HOSPITAL ISOLATED AND PURIFIED NUCLEIC ACID, HOST CELL, AND PROCESS TO PRODUCE AN ALTERNATIVE FORM OF ROTAVIRUS NSP4 ''. The non-structural protein 4 (NSP4) in the ATCC SA11 rotavirus strain has a histidine at the amino acid position 47. This substituted form is more cytotoxic than the NSP4 of the Australia rotavirus strain, which has an asparagine at the amino acid position 47. A histidine at amino acid position 47 is mutagenized to another amino acid to produce an alternative form of NSP4 that has reduced toxicity, while maintaining its antigenicity and immunogenicity. Because NSP4 has a glutamic acid at amino acid position 48 it is more cytotoxic than NSP4 with a lysine at amino acid position 48. Lysine at amino acid position 48 is mutagenized to another amino acid other than glutamic acid to produce an alternative form of NSP4 that has reduced toxicity, while maintaining its antigenicity and immunogenicity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8732098P | 1998-05-29 | 1998-05-29 | |
| PCT/US1999/011872 WO1999061621A1 (en) | 1998-05-29 | 1999-05-28 | Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9910763A true BR9910763A (en) | 2001-02-13 |
Family
ID=22204470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9910763-5A BR9910763A (en) | 1998-05-29 | 1999-05-28 | Rotaviruses non-structural protein 4 (nsp4) antigenic composition, processes to protect a mammalian host against disease caused by rotaviruses, and to improve diarrheal symptoms in a mammalian host, isolated and purified nucleic acid sequence, plasmid containing a nucleic acid sequence isolated and purified host cell and process to produce an alternative form of rotavirus nsp4 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1080200A1 (en) |
| JP (1) | JP2002516106A (en) |
| KR (1) | KR20010043868A (en) |
| CN (1) | CN1208463C (en) |
| AU (1) | AU771127B2 (en) |
| BR (1) | BR9910763A (en) |
| CA (1) | CA2328451A1 (en) |
| IL (1) | IL139997A0 (en) |
| WO (1) | WO1999061621A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009254292A (en) * | 2008-04-17 | 2009-11-05 | Tosoh Corp | Cell fusion apparatus and cell fusion method |
| CN102703475B (en) * | 2012-05-16 | 2014-05-07 | 山东省农业科学院奶牛研究中心 | Toxicity weakened NSP4 mutant gene, recombinant plasmid and recombinant bovine rotavirus |
| CN108504718A (en) * | 2018-03-27 | 2018-09-07 | 东莞市第三人民医院 | A kind of CaSR is in the metainfective expression analysis method of RV, NSP4 |
-
1999
- 1999-05-28 WO PCT/US1999/011872 patent/WO1999061621A1/en not_active Ceased
- 1999-05-28 CA CA002328451A patent/CA2328451A1/en not_active Abandoned
- 1999-05-28 EP EP99925989A patent/EP1080200A1/en not_active Withdrawn
- 1999-05-28 AU AU42164/99A patent/AU771127B2/en not_active Ceased
- 1999-05-28 JP JP2000551005A patent/JP2002516106A/en active Pending
- 1999-05-28 IL IL13999799A patent/IL139997A0/en unknown
- 1999-05-28 BR BR9910763-5A patent/BR9910763A/en not_active IP Right Cessation
- 1999-05-28 KR KR1020007013353A patent/KR20010043868A/en not_active Ceased
- 1999-05-28 CN CNB998065463A patent/CN1208463C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1080200A1 (en) | 2001-03-07 |
| AU4216499A (en) | 1999-12-13 |
| KR20010043868A (en) | 2001-05-25 |
| JP2002516106A (en) | 2002-06-04 |
| CN1302330A (en) | 2001-07-04 |
| WO1999061621A1 (en) | 1999-12-02 |
| CN1208463C (en) | 2005-06-29 |
| AU771127B2 (en) | 2004-03-11 |
| IL139997A0 (en) | 2002-02-10 |
| CA2328451A1 (en) | 1999-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412824A (en) | stable radiopharmaceutical compositions and methods for their preparation | |
| ATE157242T1 (en) | MOISTURIZING LIPSTICK COMPOSITIONS | |
| BR0306925A (en) | Stabilized adenovirus formulations | |
| ES2156199T3 (en) | INDUCTOR POLIPEPTIDE OF THE INTERFERON-GAMMA PRODUCTION, MONOCLONAL ANTIBODIES AND COMPOSITION FOR THE TREATMENT OR PREVENTION OF SENSITIVE DISEASES TO INTERFERON-GAMMA. | |
| LU93100I2 (en) | TALIMOGENE LAHERPAREPVEC AND ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES (IMLYGIC) | |
| ES2157447T3 (en) | VACCINE COMPOSITION THAT INCLUDES A CONJUGATED POLYACARIDE ANTIGEN ADSORBED IN ALUMINUM PHOSPHATE. | |
| EP0090581A3 (en) | Small peptides with the specificity of foot and mouth disease viral antigens | |
| PT1187629E (en) | ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE | |
| BR9813369A (en) | Shock absorber for use on a shoe sole, and shoe sole. | |
| AU2982889A (en) | Novel dosage form of fenofibrate | |
| BR0208183A (en) | Peptide modified by wt1 | |
| ES2184293T3 (en) | ADMINISTRABLE PHARMACEUTICAL COMPOSITIONS BY ORAL ROUTE THAT INCLUDE A BENZHYDR-PIPERAZINE AND A CYCLODEXTRINE. | |
| AU4622693A (en) | Potentiation of immunogenic response | |
| BR0005034A (en) | Herbicidal composition | |
| PE20010487A1 (en) | ROTAVIRUS VACCINE | |
| AR021806A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES ENTACAPONA AND METHOD OF PREPARATION. | |
| BR9810002A (en) | Preparation of chromatographically purified native <244> 1-at, process for preparing it, and using a support material | |
| LU91281I2 (en) | Preotact-parathyroid hormone | |
| BR0308860A (en) | Modified Factor VIII | |
| AR006514A1 (en) | A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES | |
| CO5070569A1 (en) | COMPOUND OF AMINOAZOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND MEDICINAL PRODUCT CONTAINING THEM | |
| BR0306878A (en) | Non-agonist corticotropin-releasing factor receptor receptor peptide, isolated nucleic acid and antibody, pharmaceutical composition and kit comprising said peptide and use of said peptide and nucleic acid in the manufacture of a medicament | |
| MX9301014A (en) | CYTOPROTECTOR COMPOSITIONS AND METHODS FOR PREPARING AND USING THEM. | |
| KR970707162A (en) | A novel monoclonal antibody having a class II phospholipase A2 inhibitory action and a protein comprising a part thereof (a novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing a part of the same) | |
| BR9910763A (en) | Rotaviruses non-structural protein 4 (nsp4) antigenic composition, processes to protect a mammalian host against disease caused by rotaviruses, and to improve diarrheal symptoms in a mammalian host, isolated and purified nucleic acid sequence, plasmid containing a nucleic acid sequence isolated and purified host cell and process to produce an alternative form of rotavirus nsp4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1990 DE 25/02/2009. |